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Oral propranolol as a new treatment for facial infantile hemangioma: case report
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INTRODUCTION
Hemangiomas are the most common benign tumors of infancy.
They are more common in white Caucasians, females (3:1) and pre-
mature babies (22%). Capillary hemangioma generally is presented
as a spot or well-defined purple lesion. The diagnosis of these
tumors is based on physical examination. Its incidence is 1 to 3% in
newborns. Infantile capillary hemangiomas are composed of a com-
plex mixture of clonal endothelial cells associated with pericytes,
dendritic cells, and mast cells(1-3).
During the first year of life there is a proliferative phase, with
increasing size of the lesion. After this period there is a slow spon-
taneous involution phase. Regulators of hemangioma growth and
involution are poorly understood. During the growth phase, two
major proangiogenic factors are involved: basic fibroblast growth
factor (bFGF) and vascular endothelial growth factor (VEGF); histo-
logic studies have shown that both endothelial and interstitial cells
are actively dividing in this phase. During the involution phase, apop-
tosis has been shown(3).
In up to 70% of the cases the tumor disappears completely
until 7 years of age. Unfortunately, some hemangiomas may become
large in size impinging on vital structures such as eyes, mouth, nose
or larynx, and require certain therapeutic interventions to prevent
major morbidities. Amblyopia is the most common complication
of hemangioma of the eyelid. If not treated promptly, it may lead
to irreversible visual loss in young children(1,4,5).
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RESUMO
Hemangiomas são os tumores benignos mais comuns durante o primeiro ano de vida.
Apesar do seu curso autolimitado, os hemangiomas capilares podem prejudicar funções
vitais ou sensoriais como a visão e causar alteração estética. O tratamento usual inclui
esteróides orais ou intralesionais, interferon alfa, citotoxinas, laser e ressecção cirúrgica.
Entretanto estes tratamentos não estão livres de complicações e efeitos adversos. Este
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Until today, oral or intralesional corticosteroids were the first
line of treatment for severe infantile capillary hemangiomas. Other
options include alpha interferon, vincristine, intralesional injection
of sclerosing solutions, radiotherapy, as well as pulsed dye laser and
cosmetic surgery resection(1,3,6-8).
We present a new and safe option for the treatment of severe
facial capillary hemangiomas in infancy with a nonselective beta-
blocker, low-dose oral propranolol.
CASE REPORT
A 3-month-old girl was examined for a progressively increa-
sing hemangioma of the left upper eyelid. The lesion was a pur-
plish tumor, impinging over the visual field and she could not open
her left eye (Figure 1). She was born prematurely at 32 weeks and
weighed 1800 g. The ophthalmologic evaluation was normal.
Treatment with propranolol, at an oral dose of 2 mg per kilogram
of body weight per day was initiated. The heart rate and blood
pressure were closely monitored by the pediatrician and the baby
never required hospitalization for any side effects.
One month and 15 days later, the child was able to open her
eye spontaneously and the mass in the upper eyelid was consi-
derably reduced in size. We were able to measure the visual acuity
(with Teller acuity cards) and it was worse in the left eye. Occlusion
therapy was started, 4 hs daily. After 3 months of amblyopia treatment,
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the visual acuity was the same in both eyes and occlusion therapy
was discontinued. After 5 months of treatment with oral propra-
nolol (baby at the age of 8 months) the involution of the tumor
slowed down and the dosage was slowly increased to 4 mg/kg.
After 8 months of treatment, the lesion was smaller than 1/10 of its
original size (Figure 2). The oral dosage of 4 mg/kg was maintained
until the baby was one year old. Discontinuation of therapy through
tapering of propranolol over a 3 month period was then per-
formed.
DISCUSSION
With the objective of getting better results and treating lesions
with difficult surgical access, new therapeutic modalities have been
developed. Until now, the best results were observed with steroids
and interferon-alpha with a high percentage of side effects(3).
The efficacy of propranolol in decreasing the size of hemangio-
mas was discovered by chance and published for the first time by
some authors in 2008(3). They published a case of a child with a nasal
capillary hemangioma. Despite corticosteroid treatment, the lesion
was stabilized but obstructive hypertrophic myocardiopathy deve-
loped, so the patient was treated with propranolol. The hemangio-
ma changed from intense red to purple, and it softened. The corti-
costeroids were tapered, but the hemangioma continued to im-
prove. When the corticosteroids were discontinued, no regrowth
of the hemangioma was noted.
After this first report, other cases have been published(4,5), the
greatest series with 30 and 32 patients(4-9).
Potential explanations for the therapeutic effect of propranolol -
a nonselective beta-blocker - on infantile capillary hemangiomas
include vasoconstriction, which is immediately visible as a change
in color, associated with a palpable softening of the hemangioma;
decreased expression of VEGF and bFGF genes through the down-
regulation of the RAF-mitogen-activated protein kinase pathway
(which explains the progressive improvement of the hemangioma);
and the triggering of apoptosis of capillary endothelial cells(10).
Side effects of beta-blockers are well known. Propranolol can
cause transient hypoglycemia, bradycardia, and hypotension and
may predispose patients to hypoglycemia. Bronchospasm is usually
seen as an exacerbation in patients with underlying reactive airways.
These risks can be managed. Frequent pediatric follow-ups during
therapy are important.
We did not follow any specific protocol for treatment, because at
the time we treated this first baby there were no protocols. Some
authors suggest a detailed protocol at their study(9).
In this present case, oral propranolol was very successful in rapidly
decreasing the size of the tumor and avoiding severe amblyopia,
during the most important period of the visual development, with no
side effects.
We add this Brazilian case to the few published by other collea-
gues and agree that propranolol is highly promising as an alternative
pharmacologic agent, and may emerge as the preferred treatment
for facial infantile hemangiomas.
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Figure 1. Hemangioma - before treatment. Figure 2. Hemangioma - 8 months after the beginning of the treatment.
